Study details
Enrolling now
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
NCT IDNCT05010031ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
29
Study length
about 5.1 years
Ages
18+
Locations
7 sites in NJ, NY
About this study
This trial is testing whether reduced-dose radiotherapy can be an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Palliative radiotherapy
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Procedures
radiation